Haematological Disorders Malaria Paediatrics
Conditions
Interventions
Placebo and Ferric Ammonium Citrate
Ferric Ammonium Citrate and Placebo
Placebo
Sponsors
College of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ¿ Age between 4 and 24 months ¿ Have moderate anaemia (Hb 7.0-10.0 g/dL or PCV 21 ¿ 30%) ¿ Have documented uncomplicated malaria and have completed treatment with Lumefantrine artemether (LA) ¿ HIV seronegative ¿ Be resident in the study catchment area ¿ Have no known adverse reactions to oral iron ¿ Weigh 5 kg or more ¿ Had not used the study medication in the month preceding enrolment ¿ Have written informed consent from a parent / guardian to participate in the study
Exclusion criteria
Exclusion criteria: ¿ severe malnutrition (weight-for-height <75% of expected, the presence of bi-pedal oedema) ¿ severe anaemia (Hb <7.0 g/dl or PCV <21%) ¿ persistent diarrhea ¿ Severe concomitant disease process
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of children without anaemia (Hb >10.9g/dl);Incidence of bacterial infections and clinical malaria re-infections | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of all-cause sick clinic visits;Incidence of all-cause hospital admissions;Incidence of infective-cause hospital admissions;Change in iron status markers (ZPP, MCV, sTfR, ferritin) | — |
Countries
Malawi
Contacts
Public ContactExnevia Gomo
Director of Research Support Centre
Outcome results
None listed